BAN0805/ABBV-0805 is an antibody against alpha-synuclein and a drug candidate for the treatment of Parkinson’s disease.
The goal is to develop a disease modifying treatment that stops or slows down disease progression. The project is based on research from Uppsala University in Sweden.
In 2016, BioArctic and AbbVie, a research-focused global biopharmaceutical company, entered into a strategic collaboration to develop and commercialize BioArctic’s portfolio of antibodies directed at pathological species of alpha-synuclein for the treatment of Parkinson’s disease and other potential indications.
In November 2018, AbbVie announced that they will exercise their option to license BioArctic’s alpha-synuclein antibody portfolio.
BAN0805 is the most advanced alpha-synuclein targeting antibody within the BioArctic portfolio and is being developed as a disease modifying treatment for Parkinson’s disease. AbbVie will conduct clinical development of BAN0805, now known as ABBV-0805. The first clinical study started in March 2019. BioArctic continues to develop the follow-up substances (PD 1601 and PD1602) within the framework of the collaboration with AbbVie.